Is China really producing 30% of the world’s API supply in 2025?
The claim that China accounts for “30% of global API production in 2025” can be true in some industry reports, but it depends on how “API production” is defined (by volume, value, or number of facilities) and which set of APIs is counted (generic small-molecule APIs only vs. all APIs). Without the specific source, the figure should be treated as an estimate rather than a precise statistic.
How is “API production” usually measured?
Industry statistics usually fall into one of these measurement approaches:
- By volume of active pharmaceutical ingredient (API) output.
- By manufacturing capacity (potential output).
- By exports or trade flows (which often track production indirectly).
- By value (which can differ from volume if high-value APIs dominate).
Because these methods can produce different country shares, you’ll often see different “China share” numbers across publications.
What could change China’s share by 2025?
Even if China starts from a large baseline share, the proportion can shift due to:
- Capacity expansions or shutdowns in China and India.
- Policy and compliance pressure that pushes some production to other regions.
- Demand growth for certain API categories where supply is concentrated.
Where to verify the exact 2025 “30%” figure
To confirm the “30% in 2025” claim, you need the underlying dataset or report that produced it (for example, a market research report, a government study, or an industry association statistic). If you share the report title or link you’re referencing, I can help interpret what it means (volume vs. value, scope of APIs, and whether 30% is global share or export share).
Could patent and exclusivity limits affect API production geography?
API output is influenced more by manufacturing scale and regulatory/compliance readiness than by drug patents directly. Patents shape which companies must operate (or can sell finished products), but API suppliers generally respond to demand and licensing/qualification requirements for specific molecules.
If you want, tell me whether you mean 30% of global API production, exports, or capacity, and which API category (all APIs, generics only, or specific therapeutic areas).